A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Efficacy - The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the procedure mandated by the FDA, Phase II clinical trials gauge efficacy, and Phase III trials confirm it.
Eligibility Criteria - Summary criteria for participant selection; includes Inclusion and Exclusion criteria.
Empirical - Based on experimental data, not on a theory.
Endpoint - Overall outcome that the protocol is designed to evaluate. Common endpoints are severe toxicity, disease progression, or death.
Enrolling - he act of signing up participants into a study. Generally this process involves evaluating a participant with respect to the eligibility criteria of the study and going through the informed consent process.
Epidemiology - The branch of medical science that deals with the study of incidence and distribution and control of a disease in a population.
Estimate - Numerical data calculated from sample data, or from a model, and intended to provide information about a larger set of data.
Expanded Access - Refers to any of the FDA procedures, such as compassionate use, parallel track, and treatment IND that distribute experimental drugs to participants who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials.